Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Shexiang Baoxin Pill in Patients With Ischemia With Non-Obstructive Coronary Artery: A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial

NCT04897126 is registered in ClinicalTrials.gov with Shanghai Hutchison Pharmaceuticals Limited as lead sponsor.

NCT NCT04897126
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04897126 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Shexiang Baoxin Pill in Patients With Ischemia With Non-Obstructive Coronary Artery: A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial
Lead sponsor
Shanghai Hutchison Pharmaceuticals Limited
Phase
Phase 4
Overall status
Completed
Start date
May 11, 2021
Completion date
October 25, 2023
Enrollment
240 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

angina pectoris, coronary heart disease, ischemia with non-obstructive coronary artery, x syndrome, angina